Xenios AG
7
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
28.6%
2 terminated/withdrawn out of 7 trials
50.0%
-36.6% vs industry average
0%
0 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases
Role: collaborator
Safety and Performance of the Novalung Ultimate Kit and Xenios 2.0 During Stationary Use in Hospital and Ground-based Transport of Patients on Extracorporeal Life Support (ECLS)
Role: lead
Evaluating the Safety and Performance of the MiniLung Petite Kit in Neonatal and Pediatric Patients With Acute Respiratory and Cardiac Failure
Role: lead
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
Role: lead
Early Extubation by ECCO2R Compared to IMV in Patients with Severe Acute Exacerbation of COPD
Role: lead
Effects of Blood Pulsatility on Von Willebrand Factor During ECCO2R
Role: collaborator
Synchronized Cardiac Assist for Cardiogenic Shock
Role: lead
All 7 trials loaded